Related Experiment Video
Updated: Oct 26, 2025
05:28
Evaluation of a Reliable Biomarker in a Cecal Ligation and Puncture-Induced Mouse Model of Sepsis
Published on: December 9, 2022
3.9K
GLP-1 Receptor: A New Target for Sepsis
Fuxun Yang1, Fan Zeng1, Xiaoxiu Luo1
1Department of ICU, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Frontiers in Pharmacology
|August 2, 2021
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise in treating sepsis-induced hyperglycemia. These agents may improve organ function and reduce mortality in sepsis patients with stress hyperglycemia.
Area of Science:
- Endocrinology
- Critical Care Medicine
- Pharmacology
Background:
- Sepsis is frequently associated with hyperglycemia, a condition linked to increased patient mortality.
- Stress hyperglycemia in sepsis complicates patient management and worsens outcomes.
Purpose of the Study:
- To review the potential therapeutic applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing sepsis.
- To explore GLP-1RAs as a novel approach for sepsis complicated with stress hyperglycemia.
Main Methods:
- Literature review of studies investigating GLP-1RAs in the context of sepsis and hyperglycemia.
- Analysis of the physiological and immunological effects of GLP-1RAs relevant to sepsis pathophysiology.
Main Results:
- GLP-1RAs demonstrate glucose-lowering effects, crucial for managing hyperglycemia in sepsis.
- Evidence suggests GLP-1RAs possess organ protective, immunomodulatory, and anti-inflammatory properties beneficial in sepsis.
Conclusions:
- GLP-1RAs represent a potential therapeutic strategy for sepsis patients with stress hyperglycemia.
- Further research is warranted to establish the clinical efficacy and safety of GLP-1RAs in sepsis treatment.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
498
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
498
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.2K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.2K
01:15G Protein-coupled Receptors
14.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
14.3K
01:09GPCRs Regulate Adenylyl Cylase Activity
6.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.2K